En Es
Categories

Industry News

GE Healthcare y Affibody colaboran para desarrollar trazadores para la TEP

By Medimaging en español staff writers
02 Oct 2019

Imagen: La colaboración entre GE Healthcare y Affibody busca mejorar el tratamiento de pacientes con cáncer en todo el mundo (Fotografía cortesía de Shutterstock).GE Healthcare (Chicago, IL, EUA) y Affibody AB (Solna, Suecia) formaron una colaboración estratégica para desarrollar y comercializar trazadores para TEP basados en los de Affibody, con un enfoque inicial en HER2 y PD-L1.

Affibody es una compañía biofarmacéutica, en etapa clínica, centrada en el desarrollo de biofarmacéuticos innovadores bi y multiespecíficos de próxima generación, con base en sus plataformas de tecnología patentadas únicas: las moléculas de Affibody y Albumod. Affibody opera un modelo de medicina experimental enfocado y actualmente tiene tres programas en etapa clínica. Los dos primeros son programas terapéuticos dirigidos a la psoriasis y las enfermedades autoinmunes impulsadas por la células B, respectivamente. El tercero es un programa de diagnóstico por imagenología dirigido principalmente al cáncer de mama metastásico.

La tecnología Affibody es adecuada especialmente para el desarrollo de trazadores para la imagenología TEP y ABY-025, un trazador para la TEP basado en Affibody que detecta HER2, se encuentra actualmente en desarrollo clínico. ABY-025 proporciona un enfoque novedoso, no invasivo y rentable, para diagnosticar la expresión global de HER2 en pacientes con cáncer de mama metastásico mediante imágenes TEP. Affibody trabaja actualmente junto con instituciones académicas para explorar más la utilidad clínica de ABY-025. Está en desarrollo la molécula Affibody de unión a PD-L1 como una herramienta de diagnóstico para mejorar la selección y el seguimiento de pacientes con tratamientos inmuno-oncológicos. La colaboración con GE Healthcare acelerará los estudios a través de una etapa de prueba de concepto clínica.

“El inicio de una colaboración estratégica con GE Healthcare en torno a los trazadores para la TEP refleja el compromiso de Affibody con la medicina de precisión y el tratamiento guiado por biomarcadores para los pacientes. También subraya la competitividad de nuestra tecnología y el valor de los datos clínicos que se han generado con los agentes de imagenología basados en Affibody”, dijo David Bejker, director ejecutivo de Affibody. “Creemos que nuestra colaboración con GE Healthcare para desarrollar y comercializar estos agentes de imagenología hará una contribución significativa para mejorar el tratamiento de pacientes con cáncer a nivel mundial”.

“Reconocemos que la TEP juega un papel vital en el desarrollo y uso de inmunoterapias contra el cáncer, ya que es una forma no invasiva de medir la respuesta del paciente antes, durante y después del tratamiento”, dijo Sanka Thiru, Jefe de Oncología de Imagenología Molecular, en el negocio de Diagnóstico Farmacéutico de GE Healthcare. “Nos asociamos con empresas como Affibody para crear un portafolio de agentes de imagenología molecular para oncología, centrándonos en esos biomarcadores de enfermedades que ayudarán a acelerar el desarrollo de la próxima generación de tratamientos contra el cáncer”.

Enlace relacionado:
GE Healthcare
Affibody AB



E-mail Print
FaceBook Twitter Google+ Linked in

GE Healthcare

GE Healthcare provides medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services. The company’s product areas include anesthesia delivery, diagnostic ECG, mammography, radiography, surgical imaging, maternal-infant care and clinical consumables.
More info

More articles about GE Healthcare

11 Jan 2023
GE HealthCare Acquires CT Navigation Innovator in France
GE HealthCare (Chicago, IL, USA) has entered into an agreement to acquire IMACTIS (Grenoble, France), an innovator in the rapidly growing field of computed tomography (CT) interventional guidance across an array of care areas.
Read More
05 Dec 2022
New Collaboration to Bring AR to Medical Imaging for Interventional Space
GE Healthcare (Chicago, IL, USA) and MediView XR, Inc. (Cleveland, OH, USA) have entered into a collaboration to integrate medical imaging into mixed reality solutions through the development of the OmnifyXR Interventional Suite System.
Read More
13 Oct 2022
GE Files Registration Statement for Planned Spin-Off of GE HealthCare
GE (Boston, MA, USA) has announced the filing of the Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC) for the planned spin-off of its Healthcare division, to be called GE HealthCare.
Read More
20 Jul 2022
GE's Healthcare Business to Be Named GE HealthCare
GE (Boston, MA, USA) has announced that GE HealthCare will be the name of its healthcare business following its planned separation into three industry-leading, global, investment-grade public companies.
Read More
29 Apr 2022
GE Healthcare and Medtronic Collaborate to Improve Product Access for ASCs and OBLs
GE Healthcare (Chicago, IL, USA) and Medtronic (Doral, FL, USA) have entered into a collaboration focused on the unique needs and demand for care at Ambulatory Surgery Centers (ASCs) and Office Based Labs (OBLs) that will allow customers to access extensive product portfolios, financial solutions, and exceptional service.
Read More
23 Dec 2021
GE Healthcare Completes Acquisition of BK Medical to Expand Its Ultrasound Business
GE Healthcare (Chicago, IL, USA) has completed its previously announced acquisition of BK Medical (Peabody, MA, USA; www.bkmedical.com) in a deal that would expand its ultrasound business from diagnostics into surgical and therapeutic interventions.
Read More
13 Nov 2021
GE Healthcare to be Spun Off in 2023 to Create Pure-Play Company at Center of Precision Health
General Electric (GE; Boston, MA, USA) plans to pursue a tax-free spin-off of GE Healthcare, creating a pure-play company at the center of precision health in early 2023.
Read More
30 Sep 2021
GE Healthcare Acquires BK Medical to Expand Ultrasound Portfolio into Surgical Visualization
GE Healthcare (Chicago, IL, USA) has entered into an agreement to acquire BK Medical (Peabody, MA, USA) in a deal that is expected to create value by further strengthening BK, including through significant synergies with the benefit of GE’s technology and commercial scale.
Read More

Additional news

25 Jan 2023
Global Diagnostic Imaging Services Market Driven by Rising Prevalence of Chronic Diseases
The global diagnostic imaging services market was valued at USD 40.80 billion in 2021 and is expected to register a CAGR of 5.8% during the forecast period 2022-2030 to reach USD 67.94 billion in 2030, driven by the rising prevalence of chronic diseases, increasing elderly population, and rapid technological advancements in the healthcare diagnostic industry.
Read More
25 Jan 2023
Global Endoscopy Equipment Market Driven by Growing Hospital Investment in Advanced Instruments
The global endoscopy equipment market is projected to register a CAGR of 7% from USD 28.9 billion in 2022 to USD 40.6 billion by 2027, driven by increasing demand for endoscopy to diagnose and treat target diseases, rising investments, funds, and grants by governments and other organizations across the world, and growing focus by hospitals on investing in technologically-advanced endoscopy instruments and expanding endoscopy units.
Read More
25 Jan 2023
Point-of-Care Glucose Testing Market to Reach Almost USD 6 Billion by 2032
The global point-of-care (POC) glucose testing market is projected to register a CAGR of 4.3% during the forecast period from 2022 to 2032 to reach USD 5.8 billion by 2032, driven by a rise in the geriatric population, speed & precision of POC screening, increased adoption of electronic medical information, and the higher risk of COVID-19-related mortality associated with diabetes.
Read More
24 Jan 2023
Carolina Liquid Chemistries and Diazyme Enter Into Partnership
Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.
Read More
23 Jan 2023
Mindray Defibrillators Amongst the World’s First to Receive MDR Clearance
Mindray has received the CE marking for its defibrillation product family under the European Union's newest Medical Device Regulation (MDR). With the new rule tightening the controls for defibrillation devices, Mindray has become among the first manufacturers in the world to earn MDR accreditation for product quality and effectiveness.
Read More
23 Jan 2023
Siemens Launches Centre of Excellence for Immunoassay Instrument R&D in Ireland
Siemens Healthineers has launched a Center of Excellence for Immunoassay Instrument Research and Development (R&D) in Swords, Ireland. The new center will focus on unlocking breakthrough innovations in laboratory instruments used to detect infectious diseases, cancer and blood disorders.
Read More
20 Jan 2023
Global Intensive Care Unit (ICU) Equipment Market Driven By Increasing Neurological Diseases
The global intensive care unit (ICU) equipment market was valued at USD 6.6 billion in 2021 and is estimated to register a CAGR of 3.9% from 2022 to 2031 to reach USD 9.6 billion by 2031, driven primarily by a rise in the prevalence of neurological diseases.
Read More
20 Jan 2023
Bayer Acquires Imaging AI Platform Provider in the UK
Bayer (Leverkusen, Germany) has acquired Blackford Analysis Ltd. (Edinburgh, UK), a global strategic imaging AI platform and solutions provider. The acquisition is part of Bayer's strategy to drive innovation in radiology, including the development and adoption of AI within the clinical workflow, with the goal to ultimately improve patient care and advance the company’s position in digital medical imaging.
Read More
16 Jan 2023
Medlab Middle East Sees 100% Increase in Exhibitor Numbers
Medlab Middle East, the MENA region’s largest medical laboratory exhibition and congress, has sold out its exhibitor space ahead of the show, which returns to the Dubai World Trade Centre from February 6 to 9, 2023.
Read More
Copyright © 2000-2023 TradeMed.com. All rights reserved. | Terms And Conditions